Background: Myocardial Injury After Noncardiac Surgery⁢ (MINS)

Myocardial ‍injury after⁢ noncardiac surgery (MINS) is a ⁣notable ⁢concern, contributing to substantial morbidity and mortality. Studies have shown that MINS accounts for approximately 13% of all deaths within 30 days following surgery, highlighting the urgent need for‌ effective preventative strategies.

The PREVENT-MINS Trial: Investigating ivabradine

The PREVENT-MINS ⁤trial⁣ aimed​ to ⁢determine if⁢ ivabradine, a medication used for ⁤angina and heart ⁢failure,​ could prevent MINS in patients‌ undergoing noncardiac surgery who had, or were at risk of, atherosclerotic disease.Professor Wojciech⁣ Szczeklik from Jagiellonian University Medical College in Krakow, Poland, the trial’s ‌Principal Investigator, ⁤explained that the rationale behind the study⁣ was the hypothesis that ⁣increased ‌heart ⁤rate during surgery leads to higher myocardial ‍oxygen consumption, creating⁤ a supply-demand mismatch⁢ and subsequent myocardial injury.

Beta-blockers, which‌ lower heart⁤ rate, have been shown to decrease ⁤the risk of myocardial infarction around ​the time of surgery.‌ However, these benefits can ⁢be offset by an‌ increased risk of hypotension, death, and ⁢stroke. Ivabradine selectively slows ‌heart rate,‌ offering a potential option with fewer⁢ side ⁢effects.

Trial‌ Findings: No Reduction in MINS with ‌Ivabradine

The PREVENT-MINS ‌trial concluded that ivabradine ‌did not reduce the occurrence of‌ myocardial injury after noncardiac surgery‌ (MINS). The⁣ results, presented at the European Society of Cardiology (ESC) Congress 2025, indicate that⁢ ivabradine was not effective in preventing MINS‍ in‍ the studied population.